Hudson Bay Capital Management
NRIX icon

Hudson Bay Capital Management’s Nurix Therapeutics NRIX Stock Holding History

Hudson Bay Capital Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-110,000
Closed -$2.09M – 1532
2025
Q4 		$2.09M Buy
+110,000
New +$1.58M 0.01% 709
2024
Q4 		– Sell
-125,000
Closed -$2.81M – 1055
2024
Q3 		$2.81M Buy
+125,000
New +$2.83M 0.01% 522

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Hudson Bay Capital Management's NRIX Position: Q1 2026 in Review

Hudson Bay Capital Management sold out of Nurix Therapeutics (NRIX) in Q1 2026, closing a stake of 110,000 shares — an estimated $2.09M sold.

Hudson Bay Capital Management first reported a position in NRIX in Q3 2024 and held it in 2 quarters. The position peaked at $2.81M in Q3 2024. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Hudson Bay Capital Management reported no remaining Nurix Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Hudson Bay Capital Management sold 110,000 Nurix Therapeutics shares in Q1 2026, an estimated $2.09M.
  • Hudson Bay Capital Management first reported a position in Nurix Therapeutics in Q3 2024 and held it in 2 quarters.
  • Hudson Bay Capital Management's Nurix Therapeutics position peaked at $2.81M in Q3 2024.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.